GHRS

GH ResearchB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

Current thesis

The constructive view is that GH001 now has peer-reviewed Phase 2b data, the FDA hold has been lifted, and cash was reported at $280.7 million at year-end 2025, giving GHRS a funded shot at moving into a global pivotal program if FDA alignment is achieved [#PR-2026-01-05] [#PR-2026-03-05] [#PR-2026-03-25].

Posture

Constructive

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite, 7D delta +1.4.

What can break

FDA hold removal helps, but successful FDA alignment on the planned global Phase 3 design is still an unresolved execution gate.

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $24.00 · Bull $36.00 · Bear $11.00

Data freshness

Prices

As of 2026-06-03

Fundamentals

As of 2026-06-02 • Vendor: Data Vendor v1

Scores

As of 2026-06-03 • Model: HYBRID_IC_RP

AI Memo

As of 2026-04-28 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-06-03

Supporting evidence

What

Grade B · Constructive

Confidence Medium · Net Neutral

Target $38.13

Why

Momentum93 · Δ7d +1.4

Value41 · Δ7d +0.0

Sentiment42 · Δ7d -6.4

So what

Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Lead driver: Momentum · See technicals

Momentum

34% active weight

Current posture

7d trendImproving

Δ7d

+1.4

Δ21d

+0.6

Value

32% active weight

Current posture

7d trendFlat

Δ7d

+0.0

Δ21d

+0.2

Sentiment

33% active weight

Current posture

7d trendSoftening

Δ7d

-6.4

Δ21d

-7.6

Why this grade

Composite grade B. Momentum 93.2 / Value 41.1 / Sentiment 41.6

Fundamentals (TTM)

As of 2026-06-02

Market Cap

$1.71B

Beta

0.98

Shares Out

62.03M

P/E (TTM) · Derived

-36.6

P/S (TTM)

P/FCF (TTM) · Derived

-38.49

Rev YoY

EPS YoY

+2.9%

Gross Margin

Op Margin

Net Debt

-$148.7M

Current Ratio

28.32

As of 2026-06-03 • Updated nightlySource: Internal modelMethodology